December 5, 2022Open Access

Long‐acting injectable cabotegravir forPrEP: A game‐changer inHIVprevention?

Key Points

Key points are not available for this paper at this time.

Abstract

CAB-LA has not yet achieved its full potential in HIV prevention, and strong commitment from all stakeholders is required to push CAB-LA as a game-changer in HIV response.

Read Full Paperexternally

问 AI

Bookmark

View Full Paper

Cite This Study

Liégeon et al. (Mon,) studied this question.

synapsesocial.com/papers/69d7db05ec32c73b01ae30da https://doi.org/https://doi.org/10.1111/hiv.13451

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study2023 · 2 citations
2Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women2021 · 859 citations
3Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial2020 · 173 citations
4Long-Acting Cabotegravir Protects Macaques Against Repeated Penile Simian-Human Immunodeficiency Virus Exposures2020 · 19 citations
5Drug Resistance During HIV Pre-Exposure Prophylaxis2019 · 93 citations

问 AI

Bookmark

View Full Paper